The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ketamine plus psychotherapy for "excellent" PTSD

2.

New imaging guidelines for head and neck cancers, a step toward practice change

3.

Scientists develop scans that light up aggressive cancer tumors for better treatment

4.

Higher levels of HIF2α found to slow down aggressive childhood cancer

5.

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot